Enumeration of viable CD34+ cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit

Dauber, Katrin; Becker, Daniela; Odendahl, Marcus; Seifried, Erhard; Bönig, Halvard; Tonn, Torsten

doi:10.3109/14653249.2010.529894

Cited by 49 publications

(52 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharm., as 7AAD-negative, CD34+ /CD45dim/SSC-lo/FSC-lomid events (PANEL 1, not shown), using an IVD-grade commercial HSC enumeration platform, SCE (BD, Heidelberg, Germany) [13]. The ISHAGE panel was subsequently extended to contain antibodies against CD133 and KDR for recognition of putative EPCs among the ISHAGE-HSCs, and against CD73 and CD271 for recognition of putative MSCs among the CD45-negative cells (PANEL 2, see Fig.…”

Section: Methodsmentioning

confidence: 99%

Safety and feasibility of cell-based therapy of autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundLocal implantation of ex vivo concentrated, washed and filtrated human bone marrow-derived mononuclear cells (BMC) seeded onto β-tricalciumphosphate (TCP) significantly enhanced bone healing in a preclinical segmental defect model. Based on these results, we evaluated in a first clinical phase-I trial safety and feasibility of augmentation with preoperatively isolated autologous BMC seeded onto β-TCP in combination with angle stable plate fixation for the therapy of proximal humeral fractures as a potential alternative to autologous bone graft from the iliac crest.Methods10 patients were enrolled to assess whether cell therapy with 1.3 × 106 autologous BMC/ml/ml β-TCP, collected on the day preceding the definitive surgery, is safe and feasible when seeded onto β-TCP in patients with a proximal humeral fracture. 5 follow-up visits for clinical and radiological controls up to 12 weeks were performed.Resultsβ-tricalciumphosphate fortification with BMC was feasible and safe; specifically, neither morbidity at the harvest site nor at the surgical wound site were observed. Neither local nor systemic inflammation was noted. All fractures healed within the observation time without secondary dislocation. Three adverse events were reported: one case each of abdominal wall shingles, tendon loosening and initial screw perforation, none of which presumed related to the IND.ConclusionsCell therapy with autologous BMC for bone regeneration appeared to be safe and feasible with no drug-related adverse reactions being described to date. The impression of efficacy was given, although the study was not powered nor controlled to detect such. A clinical trial phase-II will be forthcoming in order to formally test the clinical benefit of BMC-laden β-TCP for PHF patients. Trial registration The study was registered in the European Clinical Trial Register as EudraCT No. 2012-004037-17. Date of registration 30th of August 2012. Informed consent was signed from all patients enrolled.

show abstract

Section: Methodsmentioning

confidence: 99%

Safety and feasibility of cell-based therapy of autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Circulating CD34 + cells were enumerated using single-platform flow cytometry 2–4 h after the ninth dose, as described. 102 Donors receiving NRI or β-blockers were typical for MURD donors, 92 that is, in terms of donor epidemiology (age, sex and body mass index), there were no differences between the groups. Mobilization was neither enhanced by NRI nor suppressed by β-blockers (mean + s.d.…”

Section: Figurementioning

confidence: 95%

Hematopoietic stem cell mobilization: updated conceptual renditions

2012

View full text Add to dashboard Cite

Despite its specific clinical relevance, the field of hematopoietic stem cell mobilization has received broad attention, owing mainly to the belief that pharmacologic stem cell mobilization might provide clues as to how stem cells are retained in their natural environment, the bone marrow ‘niche’. Inherent to this knowledge is also the desire to optimally engineer stem cells to interact with their target niche (such as after transplantation), or to lure malignant stem cells out of their protective niches (in order to kill them), and in general to decipher the niche’s structural components and its organization. Whereas, with the exception of the recent addition of CXCR4 antagonists to the armamentarium for mobilization of patients refractory to granulocyte colony-stimulating factor alone, clinical stem cell mobilization has not changed significantly over the last decade or so, much effort has been made trying to explain the complex mechanism(s) by which hematopoietic stem and progenitor cells leave the marrow. This brief review will report some of the more recent advances about mobilization, with an attempt to reconcile some of the seemingly inconsistent data in mobilization and to interject some commonalities among different mobilization regimes.

show abstract

“…For human studies, peripheral blood samples were analyzed using the lyse-no-wash single-platform SCE (BD, Heidelberg, Germany), as described [17] for side-scatter low M A N U S C R I P T A C C E P T E D …”

Section: Phenotypic Characterization Of Hspc Subsets By Flow Cytometrymentioning

confidence: 99%

Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak

Winkler

Wiercinska

Barbier

et al. 2016

Experimental Hematology

Self Cite

View full text Add to dashboard Cite

Enumeration of viable CD34+ cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit

Cited by 49 publications

References 22 publications

Safety and feasibility of cell-based therapy of autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans

Safety and feasibility of cell-based therapy of autologous bone marrow-derived mononuclear cells in plate-stabilized proximal humeral fractures in humans

Hematopoietic stem cell mobilization: updated conceptual renditions

Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak

Contact Info

Product

Resources

About